Summary The aim of this study was to determine the correlation between changes in collagen metabolites (ICTP, mature cross-linked carboxyterminal telopeptide of type collagen; PINP, the amino-terminal propeptide of type procollagen) and bone mineral density (BMD) in 206 pre-and post-menopausal breast cancer patients with non-metastatic disease. All patients received adjuvant cancer treatmentpremenopausal patients chemotherapy and post-menopausal patients anti-oestrogens. In addition, the patients were also randomized to receive oral clodronate 1600 mg daily for 3 years. BMD was measured at baseline and at 1 and 2 years, the collagen metabolites at baseline and at 1 year. There was a highly significant negative correlation between the changes in PINP and BMD in lumbar spine and femoral neck from baseline to 12 months in all patients (r, = -0.68, P < 0.0001, and -0.45, P < 0.0001, respectively), and in pre-and post-menopausal patients separately.
collagen) and formation markers of bone (circulating concentrations of alkaline phosphatase, osteocalcin and carboxy-terminal propeptide of type I procollagen) increase significantly after menopause. During hormone replacement therapy, these markers decrease to the premenopausal level (Johansen et al, 1987 Riis et al, 1988; Hassager et al, 1991;  Riis, 1991 Riis, , 1993 Uebelhart et al, 1991; Garnero et al, 1994a; Bonde et al, 1995) . A decrease in bone turnover markers has also been documented during calcitonin and bisphosphonate treatment in post-menopausal osteoporosis (Garnero et al, 1994b; Gertz et al, 1994; Nielsen et al, 1994; Lyritis et al, 1995; Pedrazzoni et al, 1995) . The best correlation between bone markers and bone loss rate, so far, has been demonstrated by combining measurements of several resorption and formation markers  Riis, 1991 Riis, , 1993 Uebelhart et al, 1991; Pansini et al, 1992; Seibel et al, 1993) .
As type I collagen is the most common protein in the skeleton, comprising about 90% of the organic matrix in bone tissue (Melkko et al, 1990) , assays of the turnover of this protein could be good markers of bone turnover. A radioimmunoassay of the breakdown of mature type I collagen ICTP has recently been shown to be a sensitive marker of bone resorption in different diseases involving increased pathological degradation of collagen (Elomaa et al, 1992; Hakala et al, 1993; Risteli et al, 1993; De la Piedra et al, 1994; Kylmala et al, 1995; Blomqvist et al, 1996) . The results of ICTP as a resorption marker in post-menopausal osteoporosis have been conflicting (Charles et al, 1994; Gamero et al, 1994b; Hassager et al, 1994; Valimaki et al, 1994; Pedrazzoni et al, 1995) . Amino-terminal propeptide of type I procollagen, PINP, is a new marker intended to reflect the synthesis of type I collagen (Melkko et al, 1996) . In osteoporosis, the changes in PINP levels follow the concentrations of osteocalcin and alkaline phosphatase, but differ from the values of PICP, which is the carboxy-terminal analogue of PINP (Sharp et al, 1996) .
We have previously reported the results of BMD measurements in 206 primary early-stage breast cancer patients without metastases (Saarto et al, 1997a and b) . Briefly, bone loss in premenopausal patients correlated significantly with the ovarian dysfunction induced by adjuvant chemotherapy. The most marked bone loss was seen in those patients rendered amenorrhoeic by chemotherapy. Clodronate significantly reduced the bone loss both in lumbar spine and in femoral neck in all premenopausal women (in the control group -5.9% and -0.2% and in the clodronate group -2.2% and + 0.9% respectively) and in amenorrhoeic patients separately (in the control group -9.5% and -4.6% and in the clodronate group -5.9% and -0.4% respectively). In postmenopausal patients, anti-oestrogen treatment with tamoxifen or toremifene seemed to prevent the development of postmenopausal osteoporosis. Clodronate treatment significantly improved BMD of lumbar spine and femoral neck in postmenopausal patients (in the control group -0.5% + 0.5% and in the clodronate group + 2.9% and + 3.7% respectively). Here, we wanted to find out in the same patients whether changes in PINP and ICTP levels may (1) correlate with BMD behaviour and (2) predict the efficacy of clodronate therapy.
MATERIAL AND METHODS Patients and methods
The study population consisted of 206 pre-and post-menopausal women with operable breast cancer and histologically proven axillary metastases, without haematogenic metastases. Eligible for the analyses were patients who were disease free at the time of measurement of BMD and collagen metabolites. In addition, patients having bone metastases within 6 months after measurement of BMD and collagen metabolites were excluded from the analyses. Baseline adjuvant cancer treatment was six cycles of CMF chemotherapy for premenopausal patients (cyclophosphamide 600 mg m-2, methotrexate 40 mg m-2 and 5-fluorouracil 600 mg m-2) and anti-oestrogens for post-menopausal patients (tamoxifen 20 mg or toremifene 60 mg per day) for 3 years. All patients underwent surgery with axillary evacuation and total mastectomy or breast-conserving resection and post-operative radiotherapy. All patients were randomized to receive oral clodronate (Bonefos, Leiras) 1600 mg daily for 3 years or to a control group. After chemotherapy, the premenopausal patients were divided into two groups according to menstrual function at 1 year of follow-up: menstruating (regularly or irregularly) or amenorrhoeic patients. Fast bone losers were defined as patients who lost BMD by more than 3% per year. The BMD changes during the trial of 2 years have been previously reported (Saarto et al, 1 997a and b) .
Biochemical measurements were performed at the start of the study and at 12 months. All serum samples were stored at -20°C. ICTP and PINP reflect degradation and synthesis, respectively, of type I collagen, the predominant collagen in bone matrix. The methods for the PINP and ICTP assays have been described elsewhere Melkko et al, 1996) . The reference interval of ICTP for adult women is 1.7-4.6 ,ug 1-', and that of PINP 19-84 gg 1-1. The intra-and interassay coefficients of variation are 3.1-8.5% for PINP, and 2.8-6.2% and 4.1-7.9% for ICTP respectively Melkko et al, 1996) . Bone mineral density (BMD, g cm-2) was measured by dual-energy X-ray absorptiometry (DXA) using a Hologic QDR-1000 densitometer (Hologic, Waltham, MA, USA). BMD was measured at the lumbar vertebrae (LI-L4) and femoral neck in the right femoral area before initiation of therapy and at 1 and 2 years. The coefficients of variation for precision of the BMD measurements in the lumbar vertebrae and femoral neck were 0.9% and 1.2% respectively. were calculated with the CIA statistical software (Gardner et al, 1989) . Because of the problems of multiple comparisons, the significance level was set at 0.01.
RESULTS
Correlation between type I collagen metabolites and between baseline lumbar spine BMD and PINP level was also significant in post-menopausal patients, but not in premenopausal patients (Table 1) . The median concentration of ICTP at baseline was 3.8 ,ug 1-(range 1.6-17.2 ,ug 1-'), in premenopausal patients 3.5 ,ug 1-1 (range 1.6-8.3 jig 1-1) and in post-menopausal 4.0 ,ug 1-' (range 1.8-17.2 jig 1-').
Baseline ICTP level was significantly higher in post-menopausal than in premenopausal patients (P = 0.004), with no baseline differences between the premenopausal patients who, after chemotherapy, menstruated or were amenorrhoeic. The baseline ICTP value was within the reference interval in 153 patients (78%). The baseline ICTP concentrations did not correlate with baseline BMD (Table 1) .
Prediction of bone loss by type I collagen metabolites at baseline The baseline PINP level correlated positively with the BMD changes in the lumbar spine at 1 and 2 years (rS = 0.32, P < 0.0001, and rs = 0.30, P < 0.0001, respectively), but not with those in the femoral neck. The significant correlations with BMD in lumbar spine at 1 and 2 years were also seen in the group of postmenopausal, but not in that of premenopausal, patients. A marginal positive correlation was also seen between the baseline ICTP level and the BMD change in lumbar spine at 1 year (rs = 0.18, P = 0.01) ( 
Prediction of bone loss by changes in type I collagen metabolites
The Spearman's rank-order correlation coefficients between the changes observed in the markers from baseline to 12 months and the BMD changes in lumbar spine and femoral neck at 1 and 2 years are shown in Table 2 and Figure 1 . There was a highly significant negative correlation between PINP changes from baseline to 12 months and BMD changes to 1 and 2 years in all patients in lumbar spine (rs = -0.68, P < 0.0001, and -0.70, P < 0.0001) and femoral neck (rs = -0.45, P < 0.0001, and -0.5 1, P < 0.0001), and in pre-and post-menopausal patients separately. The median change in PINP level in all patients was -6.7 gg 1-' (-18.3%), in premenopausal patients + 0.6 gg 1-' (+ 1.4%), in post-menopausal patients -17.6 tg 1-1 (-41.8%) and separately in menstruating and amenorrhoeic premenopausal patients -4.6 jig 1-' (-15.7%) and + 28.4 jig 1-' (+ 61.0%) respectively (Figure 2) .
ICTP change correlated significantly negatively with lumbar spine BMD change at 1 and 2 years in all patients (rs = -0.27, P = 0.0001, and -0.31, P < 0.0001) and in premenopausal patients (rs = -0.34, P = 0.0003, and -0.38, P = 0.0002), but with femoral neck only at 2 years. No correlation was seen in post-menopausal patients ( Table 2 ). The median change in ICTP levels in all patients was -0.7 jig 1-' (-22.8%), in premenopausal patients -0.3 jig 1-' (-14.8%), in post-menopausal patients -1.0 jg 1-' (-25.0%) and in menstruating and amenorrhoeic premenopausal patients -0.6 ,ug 1-' (-20.0%) and + 0.05 ,ug 1-' (+ 1.5%) respectively. +200 +250 +450 +800 Correlation between type I collagen metabolites at 12 months and BMD changes PINP levels at 12 months correlated significantly negatively to BMD changes at and 2 years in lumbar spine (rs = -0.54, P < 0.0001, and rs = -0.59, P < 0.0001) and femoral neck (rs = -0.39, P < 0.0001, and rs = -0.47, P < 0.0001) in all patients; in the premenopausal women in lumbar spine (r = -0.46, P < 0.0001, and r, = -0.50, P < 0.0001) and femoral neck (rs = -0.37, P < 0.0001, and rs = -0.39, P < 0.0001); and in post-menopausal patients in lumbar spine (r = 0.45, P < 0.0001, and r = 0.51, P < 0.0001) and femoral neck (rs = -0.23, P = 0.026, and rs = -0.48, P < 0.0001). A marginal negative correlation was also seen in premenopausal patients between ICTP levels at 12 months and BMD changes at 1 and 2 years in lumbar spine (rs = -0.26, P = 0.005, and -0.34, P = 0.0007) and in femoral neck (rs = -0.20, P = 0.03 and -0.29, P = 0.004), but not in post-menopausal patients.
Clodronate vs control group
Baseline values of PINP were similar in the clodronate and control groups. PINP levels at 12 months were significantly lower in the clodronate group than in the control group, in all patients and also in pre-and post-menopausal patients (P < 0.0001, 0.0003 and < 0.0001 respectively). In all patients, median PINP levels decreased in the clodronate and control groups by 14.6 jig -1 (-38.7%) and 0.7 jtg 1-(-1.7%) respectively (P < 0.0001). In premenopausal patients, median PINP levels decreased with clodronate by 5.6 jg 1-1 (-16.8%), but increased without it by 9.2 tg 1-' (+ 29.5%) (P = 0.0005): in menstruating patients, the corresponding changes were -11.6 jg 1-1 (-27.6%) with and -2.1 ,ug 1-' (-3.6%) without clodronate, and in amenorrheic patients + 0.7 jg 1-' (+ 1.8%) with and + 34.5 jg 1-' (+ 83.3%) without clodronate (P = 0.003 and 0.007). In post-menopausal patients, median PINP levels decreased by 30.8 jg 1-1 (-60.8%) with and by 12.4 jg 1-1 (-25.2%) without clodronate (P < 0.0001) (Figure 3) .
The clodronate and control groups did not differ from each other by baseline or 12-month ICTP levels, nor by changes in ICTP levels from the baseline to 12 months.
DISCUSSION
In the development of osteoporosis, the rate of bone loss after menopause is at least as important as bone mass at menopause. Women who have had rapid bone loss at menopause lose, on average, twice the amount of bone mass over 12 years after menopause than normal bone losers (Hansen et al, 1991) . Several attempts have been made to identify rapid bone losers by measuring biochemical markers of bone turnover. The best correlation between bone markers and bone loss rate, so far, has been British Journal of Cancer (1998) Riis, 1991 Riis, , 1993 Uebelhart et al, 1991; Pansini et al, 1992; Seibel et al, 1993 Melkko et al, 1996) . Our study implies that the measurement of the PINP level change is an effective method to determine the rate of bone loss. In this study, the changes in PINP levels from baseline to 12 months significantly correlated with the changes in BMD of lumbar spine and femoral neck in pre-and post-menopausal women during the same time and further predicted the changes in BMD at 2 years. These correlations were seen both in pre-and in postmenopausal patients separately. In the present study, the PINP level at 12 months also correlated significantly to BMD changes. However, because of the wide individual variation in PINP levels, the changes in PINP from baseline are more useful parameters in evaluation of bone turnover rate than PINP levels at 12 months.
The response of PINP on clodronate treatment in our study was concordant with the response of other bone turnover markers on antiresorptive treatment in previous studies (Garnero et al, 1994b; Gertz et al, 1994; Nielsen et al, 1994; Lyritis et al, 1995; Pedrazzoni et al, 1995) . In the present study, PINP levels decreased more significantly in the clodronate-treated patients than in the control group. This was seen both in pre-and postmenopausal patients. Similar PINP level decreases have previously been reported during oestrogen replacement therapy in post-menopausal women. The circulating concentration of PINP decreased by 40% during the oestrogen replacement therapy reported by Sharp et al (1996) , while in our post-menopausal patients anti-oestrogen treatment with clodronate decreased the PINP level by 61% and the anti-oestrogen alone by 25%.
Baseline PINP level was significantly higher in post-menopausal patients than in premenopausal patients, reflecting higher bone turnover rate in post-menopausal women. In the case of vertebral osteoporosis, patients with higher bone turnover rate responded better to calcitonin treatment than patients with lower turnover rate (Civitelli et al, 1988) . Similarly, in the present study, the baseline PINP levels correlated positively to BMD changes in lumbar spine in post-menopausal patients, the higher the baseline PINP level the better the response to antiresorptive treatments (anti-oestrogens, clodronate). However, this correlation was only seen in postmenopausal women, which reflects that the rate of bone turnover before menopause is not correlated to that after menopause.
ICTP and BMD changes correlated significantly only in lumbar spine of premenopausal women whose rapid bone loss was a consequence of chemotherapy-induced amenorrhoea. Baseline ICTP level did not predict future changes in BMD, even though it was significantly higher in post-menopausal patients than in premenopausal patients. Neither was the efficacy of antiresorptive treatments correlated to the decrease in ICTP level. This finding agrees with previous ICTP reports in osteoporosis, in which ICTP reflected bone resorption rate, but the sensitivity was too low to predict small changes in BMD (Charles et al, 1994; Garnero et al, 1994b; Hassager et al, 1994; Pedrazzoni et al, 1995) .
Our results indicate that the amino-terminal propeptide of type I procollagen (PINP) is a sensitive marker of bone metabolic activity. Changes in PINP levels significantly correlated with BMD changes and predicted further changes in BMD. The changes in PINP level also reflected the efficacy of antiresorptive treatment with clodronate.
